Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-01-24
2006-01-24
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S274100
Reexamination Certificate
active
06989395
ABSTRACT:
Compounds of the following backbone structure:which are useful as Tumor necrosis factor (TNF) inhibitors in treating disease related to elevated TNF.
REFERENCES:
patent: 3707475 (1972-12-01), Lombardino
patent: 3940486 (1976-02-01), Fitzi
patent: 4175127 (1979-11-01), Bender et al.
patent: 4503065 (1985-03-01), Wilkerson
patent: 5102848 (1992-04-01), Soo et al.
patent: 5179117 (1993-01-01), Maduskuie
patent: 5593991 (1997-01-01), Adams et al.
patent: 5593992 (1997-01-01), Adams et al.
patent: 5656644 (1997-08-01), Adams et al.
patent: 5663334 (1997-09-01), Sheldrake et al.
patent: 5670527 (1997-09-01), Adams et al.
patent: 5686455 (1997-11-01), Adams et al.
patent: 0229496 (1987-07-01), None
patent: 0236628 (1987-09-01), None
patent: 0275820 (1987-11-01), None
patent: 0264883 (1988-04-01), None
patent: 0274353 (1988-07-01), None
patent: 0424195 (1991-04-01), None
patent: 0506437 (1992-09-01), None
patent: 0653421 (1995-05-01), None
patent: 0790238 (1997-08-01), None
patent: 2306108 (1997-04-01), None
patent: 7053546 (1995-02-01), None
patent: 9124640 (1997-05-01), None
patent: 8302611 (1983-08-01), None
patent: 9103243 (1991-03-01), None
patent: 9205148 (1992-04-01), None
patent: 9314081 (1993-07-01), None
patent: 9314082 (1993-07-01), None
patent: 9323392 (1993-11-01), None
patent: 9419350 (1994-09-01), None
patent: 9503297 (1995-02-01), None
patent: 9513067 (1995-05-01), None
patent: 9616040 (1996-05-01), None
patent: 9621452 (1996-07-01), None
patent: 9705877 (1997-02-01), None
patent: 9705878 (1997-02-01), None
patent: 0712876 (1997-04-01), None
patent: 9716426 (1997-05-01), None
patent: 9716441 (1997-05-01), None
patent: 9716442 (1997-05-01), None
patent: 9735855 (1997-10-01), None
Graninger et al. Curr. Opin. Rhematol. 13(3) 209-13, 2001.
Shaw et al. Expert Opin. Investig. Drugs 9(7) 1469-1478, 2000.
Asltes et al. “Acyl-COA: cholesterol O-acyltransferase (ACAT) Inhibitors. 2-(1,3-D Ioxan-2-yl)-4,5-diphenyl-1H-imidazoles as potent inhibitors of ACAT.” Journal of Medicinal Chemistry, 39(7):1423-1432 (1996).
Schmidt et al. “Die Gallussaureester des Glycerom/” Chemische Beritchte, 89(2):283-290 (1956).
Searles et al. “Oxetanes IX, Structural and solvent effects in the reaction of gamma-bromoalcohols with base.” Journal of Organic Chemistry, 24(12):1839-1844 (1960).
Nys et al. “The chemistry of the delta2-dihydrazoles,” Bulletin Des Societies Chimique Belges. 65:37-402 (1956).
Czech et al. “Synthesis of Benzo-13-crown-4 derivatives.” Journal of Heterocyclic Chemistry. 28:1387-1394 (1991).
Shiuh-Tzung et al., “Synthesis of amino-containing phosphines. The use of iminophosphorane as a protecting for primary amines.” Journal of Organic Chemistry 57:6079-6080 (1992).
Mozingo et al. Hydrogenolysis of beta-oxygenated esters to glycoles. JACS 70:227-229 (1948).
Cherbuliez et al., “Recherches sur la formation et al tranformation dcs esters,” Helvetica Chimica Acta 50(8): 2563-2569 (1967).
Broadbent et al., “Novel Heteroyclic Systems.” J. Hetero. Chem. 13:337-348(1976).
Gallagher et al. “2,4,5-triarylimidazole inhibitors of IL-1 biosynthesis.” Bioorganic and Medicinal Chemistry Letters, 5(11):1171-1176 (1995).
Gallagher et al. “Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase,” Bioorganic & Medicinal Chemistry 5(1):49-64 (1997).
Boehm et al. 1-substituted 4-aryl-5-pyridinylimidazoles; A new class of cytokine suppressive drugs with low 5-lipoxygense and cyclooxygenase inhibitory potency, J. Med. Chem. 39(20):3929-3937 (1996).
Hadri et al. A convenient synthesis of cis-4-(sulfomethyl) piperidine-2-carboxylic acid. J. Hetero. Chem. 30(3):631-635 (1993).
Procopion et al. “A novel oxidative rearrangement of a pentasubstituted pyrrole to an unsaturated hydroxy gamma-lactam.” J. Chem. Soc., Perkin Trans. 1(3):245-247 (1994).
Gilligan, et al. “Novel piperidine sigma-receptor ligands as potential antipsychotic drugs.” J. Med. Chem. 35(23):4344-4361 (1992).
Senderoff, et al. “Synthesis of carbon-14-labeled 6-(4-fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidazo [2,1-b] thiazole.” J. Labelled Compd. Radiopharm. 24(8):971-978 (1987).
Lantos et al. “Antiinflammatory activity of 5,6-diaryl-2,3-dihydroimidazo [2,1-b] tiazoles, Isomeric 4-pyridyl and 4-substituted-phenyl derivatives.” J. Med. Chem. 27(1):72-75 (1984).
Procopiou et al. “Inhibitors of cholesterol biosynthesis. 2 3,5-dihydroxy-7-(N-pyrrolyl)-6-heptenoatoes, a novel series of HMG-CoA Reductase Ihnibitors.” J. Med. Chem. 36:3658-3662 (1993).
Bamborough Paul L.
Collis Alan J.
Halley Frank
Lewis Richard A.
Lythgoe David J.
Aventis Pharma Limited
Balasubramanian Venkataraman
Lin Jiang
LandOfFree
Imidazolyl-cyclic acetals does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazolyl-cyclic acetals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazolyl-cyclic acetals will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3591062